Home>>Signaling Pathways>> Apoptosis>> RIP kinase>>RIP2 kinase inhibitor 2

RIP2 kinase inhibitor 2

Catalog No.GC32860

RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.

Products are for research use only. Not for human use. We do not sell to patients.

RIP2 kinase inhibitor 2 Chemical Structure

Cas No.: 1581270-11-2

Size Price Stock Qty
10mM (in 1mL DMSO)
$306.00
In stock
1mg
$129.00
In stock
5mg
$321.00
In stock
10mg
$459.00
In stock
50mg
$1,379.00
In stock
100mg
$1,930.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.

RIP2 kinase inhibitor 2 is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase is a TKL family serine/threonine protein kinase involved in innate immune signaling. Following activation, RIP2 kinase associates with NODI or NOD2 and appears to function principally as a molecular scaffold to bring together other kinases (TAK1, Ικκα/β/γ) involved in NF-κβ and mitogen-activated protein kinase activation[1].

[1]. Linda N. Casillas, et al. Amino-quinolines as kinase inhibitors. PCT Int. Appl. (2014), WO 2014043437 A1 20140320.

Reviews

Review for RIP2 kinase inhibitor 2

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RIP2 kinase inhibitor 2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.